This patient did not have a pre-PARPi sample available to ascertain if the variant was acquired during PARPi treatment and it is unclear what the implication of this mutation might be for resistance, rather than cancer inception, particularly in the context of a germline BRCA2 mutation. This evidence concerns the gene BRCA2 and cancer.